• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

HDAC2 Gene Record

  • Summary
  • Interactions
  • Claims
  • HDAC2 3066 Druggable GenomeDrug Resistance

    Alternate Names:

    3066
    HISTONE DEACETYLASE 2
    HDAC2
    HD2
    RPD3
    YAF1
    605164
    4853
    ENSG00000196591
    OTTHUMG00000015411
    Q92769
    BE0002366
    2616
    HDAC2_HUMAN
    T51191
    2578
    NM_001527
    NP_001518

    Gene Info:

    Target Class Enzymes
    Target Subclass EC:3.5.1.98
    Target Main Class Enzymes
    Target Subclass 3.5.1.98
    Gene Biotype PROTEIN_CODING
    GuideToPharmacology Gene Category Name 3.5.1.- Histone deacetylases (HDACs)
    GuideToPharmacology Gene Category ID 848
    (11 More Sources)

    Gene Categories: Category Details

    DRUG RESISTANCE
    TRANSCRIPTION FACTOR BINDING
    DRUGGABLE GENOME
    ENZYME
    TRANSCRIPTION FACTOR

    Publications:

    Shi Y et al., 2007, Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition., Bioorg Med Chem Lett
    Kozlov MV et al., 2015, Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6., Bioorg Med Chem Lett
    Ito et al., 2002, A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression., Proc. Natl. Acad. Sci. U.S.A.
    Cosio et al., 2004, Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages., J. Exp. Med.
    Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem
    Xu et al., 2007, Histone deacetylase inhibitors: molecular mechanisms of action., Oncogene
    Grolla AA et al., 2009, Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases., J Med Chem
    Hutt DM et al., 2010, Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis., Nat Chem Biol
    Yang W et al., 2015, Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors., Bioorg Med Chem
    Guerrant W et al., 2013, Dual-acting histone deacetylase-topoisomerase I inhibitors., Bioorg Med Chem Lett
    Guerrant W et al., 2012, Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors., J Med Chem
    Pérez-Balado C et al., 2007, Bispyridinium dienes: histone deacetylase inhibitors with selective activities., J Med Chem
    Souto JA et al., 2010, Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues., J Med Chem
    Neelarapu R et al., 2011, Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes., J Med Chem
    Day JA et al., 2013, Investigating the selectivity of metalloenzyme inhibitors., J Med Chem
    Olson DE et al., 2013, Discovery of the first histone deacetylase 6/8 dual inhibitors., J Med Chem
    Dallavalle S et al., 2009, Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors., Eur J Med Chem
    Thomas M et al., 2008, Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy., Bioorg Med Chem
    Marson CM et al., 2013, Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit., J Med Chem
    Khan et al., 2008, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors., Biochem. J.
    Marson CM et al., 2015, Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit., J Med Chem
    Mimori S et al., 2013, 4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor., Bioorg Med Chem Lett
    Herman D et al., 2006, Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia., Nat Chem Biol
    VanderMolen et al., 2011, Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma., J. Antibiot.
    Campbell CT et al., 2008, Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells., J Med Chem
    Olsen CA et al., 2009, Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides., J Med Chem
    Fass et al., 2010, Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin., ACS Med Chem Lett
    Aggarwal R et al., 2017, Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies., J Clin Oncol
    Perrino E et al., 2008, New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity., Bioorg Med Chem Lett
    Petrelli R et al., 2014, From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine., Bioorg Med Chem Lett
    Marrazzo A et al., 2011, Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells., Eur J Med Chem
    Charrier C et al., 2009, Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression., J Med Chem
    Hong S et al., 2015, Efficient synthesis and biological activity of Psammaplin A and its analogues as antitumor agents., Eur J Med Chem
    Hirata Y et al., 2012, Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain., Bioorg Med Chem Lett
    Benelkebir H et al., 2011, Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability., Bioorg Med Chem
    Bhansali P et al., 2014, Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups., Eur J Med Chem
    Lin et al., 2008, Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2., Cancer Res.
    Barnes PJ, 2006, How corticosteroids control inflammation: Quintiles Prize Lecture 2005., Br J Pharmacol
  • CINNAMIC ACID HYDROXAMATE   HDAC2

    Interaction Score: 2.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24074025


    Sources:
    DTC

  • TIXOCORTOL   HDAC2

    Interaction Score: 1.07

    Interaction Types & Directionality:
    stimulator (activating)

    Interaction Info:

    PMIDs:
    16604091


    Sources:
    DrugBank

  • MOCETINOSTAT   HDAC2

    Interaction Score: 0.66

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name MGCD-0103
    Novel drug target Established target
    Mechanism of Interaction Histone deacetylase 2 inhibitor

    PMIDs:
    23829483 17868033 26287310


    Sources:
    DTC TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

  • NANATINOSTAT   HDAC2

    Interaction Score: 0.54

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    None found


    Sources:
    TTD TALC GuideToPharmacology

  • BELINOSTAT   HDAC2

    Interaction Score: 0.46

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    25937017


    Sources:
    DTC TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

  • VORINOSTAT   HDAC2

    Interaction Score: 0.46

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    24694055 17694093 19344175 19966789 26211462 23622981 22260166 17447750 20491440 21548582 24074025 23672185 19084294


    Sources:
    TEND DTC TdgClinicalTrial DrugBank TALC GuideToPharmacology ChemblInteractions

  • ENTINOSTAT   HDAC2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes

    PMIDs:
    19966789 20491440 22321215


    Sources:
    DTC TALC GuideToPharmacology ChemblInteractions

  • ABEXINOSTAT   HDAC2

    Interaction Score: 0.39

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name PCI-27483, CRA-024781
    Novel drug target Established target
    Notes

    PMIDs:
    28221861


    Sources:
    TdgClinicalTrial CIViC TALC

  • TACEDINALINE   HDAC2

    Interaction Score: 0.39

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes
    Direct Interaction? False

    PMIDs:
    18692397


    Sources:
    DTC GuideToPharmacology ChemblInteractions

  • ROMIDEPSIN   HDAC2

    Interaction Score: 0.38

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    21587264


    Sources:
    TEND TdgClinicalTrial DrugBank TALC GuideToPharmacology ChemblInteractions

  • TRICHOSTATIN   HDAC2

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21055848 16921367 19966789 19385600 24074025


    Sources:
    DTC

  • PANOBINOSTAT   HDAC2

    Interaction Score: 0.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Panobinostat
    Notes

    PMIDs:
    24694055


    Sources:
    DTC TdgClinicalTrial TALC GuideToPharmacology

  • CUDC-101   HDAC2

    Interaction Score: 0.31

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TALC GuideToPharmacology ChemblInteractions

  • APICIDIN   HDAC2

    Interaction Score: 0.29

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    19705846


    Sources:
    DTC GuideToPharmacology

  • OXTRIPHYLLINE   HDAC2

    Interaction Score: 0.29

    Interaction Types & Directionality:
    activator (activating)

    Interaction Info:

    PMIDs:
    12070353 15337792


    Sources:
    DrugBank

  • CHIDAMIDE   HDAC2

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Chidamide, HBI-8000
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • SCRIPTAID   HDAC2

    Interaction Score: 0.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? False
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    19966789


    Sources:
    DTC GuideToPharmacology

  • GIVINOSTAT   HDAC2

    Interaction Score: 0.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name ITF2357,Givinostat
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TALC GuideToPharmacology

  • VALPROIC ACID   HDAC2

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18294844 16921367 25304896


    Sources:
    DTC

  • CITARINOSTAT   HDAC2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • SUBEROHYDROXAMIC ACID   HDAC2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16921367


    Sources:
    DTC

  • CHEMBL1650245   HDAC2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24044874


    Sources:
    DTC

  • AMINOPHYLLINE   HDAC2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    activator (activating)

    Interaction Info:

    PMIDs:
    12070353


    Sources:
    DrugBank

  • PHENYLBUTYRYLHYDROXAMIC ACID   HDAC2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21874153


    Sources:
    DTC

  • BUTYRYLHYDROXAMIC ACID   HDAC2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21874153


    Sources:
    DTC

  • CHEMBL324053   HDAC2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16921367


    Sources:
    DTC

  • CHEMBL117487   HDAC2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17566732


    Sources:
    DTC

  • DOMATINOSTAT   HDAC2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name 4SC-202
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • BUTANOIC ACID   HDAC2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19053749


    Sources:
    DTC

  • PRACINOSTAT   HDAC2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name SB939
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial DrugBank

  • RICOLINOSTAT   HDAC2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? False
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • PSAMMAPLIN A   HDAC2

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25884112


    Sources:
    DTC

  • PHENYLBUTANOIC ACID   HDAC2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24044874


    Sources:
    DTC

  • LARGAZOLE   HDAC2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21420302 25203782 20491440


    Sources:
    DTC

  • DEPAKOTE   HDAC2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • AN-9   HDAC2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • FIMEPINOSTAT   HDAC2

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology ChemblInteractions

  • PANOBINOSTAT LACTATE   HDAC2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Histone deacetylase inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • THEOPHYLLINE   HDAC2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    activator (activating)

    Interaction Info:

    PMIDs:
    12070353 15337792


    Sources:
    DrugBank

  • FLUVASTATIN   HDAC2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    18381445


    Sources:
    DrugBank

  • DACINOSTAT   HDAC2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • RESMINOSTAT   HDAC2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name Resminostat
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • QUISINOSTAT   HDAC2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • AR-42   HDAC2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name AR-42

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • 7-ETHYL-10-HYDROXYCAMPTOTHECIN   HDAC2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23622981


    Sources:
    DTC

  • HINOKITIOL   HDAC2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PRAVASTATIN   HDAC2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    18381445


    Sources:
    DrugBank

  • PAZOPANIB   HDAC2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28221861


    Sources:
    CIViC

  • LOVASTATIN   HDAC2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:

    PMIDs:
    18381445


    Sources:
    DrugBank

  • SIMVASTATIN   HDAC2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    18381445


    Sources:
    DrugBank

  • OLAPARIB   HDAC2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family PARP inhibitor
    Alteration HDAC2:.

    PMIDs:
    None found


    Sources:
    CGI

  • ATORVASTATIN   HDAC2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    18381445


    Sources:
    DrugBank

  • DAUNORUBICIN   HDAC2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • Ensembl: ENSG00000196591

    • Version: 101_38

    Alternate Names:
    HDAC2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: Q92769

    • Version: January-2014

    Alternate Names:
    HDAC2 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:3.5.1.98

    Publications:

  • TEND: Q92769

    • Version: 01-August-2011

    Alternate Names:
    HDAC2 Gene Symbol
    HDAC2_HUMAN Uniprot Id
    ENSG00000196591 Ensembl Gene Id

    Gene Info:
    Target Main Class Enzymes
    Target Subclass 3.5.1.98

    Publications:

  • GuideToPharmacology: 3066

    • Version: 29-September-2020

    Alternate Names:
    4853 HUGO Gene ID
    4853 HUGO Gene Symbol
    histone deacetylase 2 HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name 3.5.1.- Histone deacetylases (HDACs)
    GuideToPharmacology Gene Category ID 848

    Gene Categories:
    ENZYME

    Publications:

  • CIViC: HDAC2

    • Version: 14-September-2020

    Alternate Names:
    3066 Entrez Gene ID
    2578 CIViC Gene ID

    Gene Info:

    Publications:
    Aggarwal R et al., 2017, Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies., J Clin Oncol

  • DrugBank: BE0002366

    • Version: 5.1.7

    Alternate Names:
    HDAC2 DrugBank Gene Name
    Q92769 UniProt Accession
    3066 Entrez Gene Id

    Gene Info:

    Publications:
    Lin et al., 2008, Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2., Cancer Res.
    Ito et al., 2002, A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression., Proc. Natl. Acad. Sci. U.S.A.
    Cosio et al., 2004, Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages., J. Exp. Med.

  • DTC: HDAC2

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Shi Y et al., 2007, Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition., Bioorg Med Chem Lett
    Kozlov MV et al., 2015, Pyridine hydroxamic acids are specific anti-HCV agents affecting HDAC6., Bioorg Med Chem Lett
    Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem

  • HingoraniCasas: ENSG00000196591

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000196591 Gene Symbol
    HDAC2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: HDAC2

    • Version: chembl_23

    Alternate Names:
    HDAC2 GENE_SYMBOL
    Histone deacetylase 2 UNIPROT
    HD2 UNIPROT

    Gene Info:

    Publications:

  • TALC: HDAC2

    • Version: 12-May-2016

    Alternate Names:
    HDAC2 Gene Symbol

    Gene Info:

    Publications:

  • Pharos: HDAC2

    • Version: 03-September-2020

    Alternate Names:
    Histone deacetylase 2 Gene Name
    Q92769 UniProt ID

    Gene Info:

    Gene Categories:
    TRANSCRIPTION FACTOR

    Publications:

  • Tempus: HDAC2

    • Version: 11-November-2018

    Alternate Names:
    HDAC2 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: Histone deacetylase 2

    • Version: 2020.06.01

    Alternate Names:
    HDAC2 TTD Gene Abbreviation
    T51191 TTD Target ID

    Gene Info:

    Publications:

  • CGI: HDAC2

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:

  • GO: HDAC2

    • Version: 05-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE, TRANSCRIPTION FACTOR BINDING

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21